Aralez Pharmaceuticals (ARZ) Shares Down 8.2%

Shares of Aralez Pharmaceuticals Inc (TSE:ARZ) dropped 8.2% during mid-day trading on Friday . The stock traded as low as C$2.00 and last traded at C$2.02. Approximately 11,800 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 30,885 shares. The stock had previously closed at C$2.20.

Separately, HC Wainwright restated a “buy” rating on shares of Aralez Pharmaceuticals in a research report on Monday.

The company has a market cap of $119.06 and a PE ratio of -1.31.

Aralez Pharmaceuticals (TSE:ARZ) last issued its earnings results on Thursday, November 9th. The company reported C($0.46) earnings per share for the quarter, beating the consensus estimate of C($0.50) by C$0.04. Aralez Pharmaceuticals had a negative net margin of 100.42% and a negative return on equity of 146.16%. The business had revenue of C$30.53 million for the quarter, compared to analyst estimates of C$29.81 million.

COPYRIGHT VIOLATION NOTICE: “Aralez Pharmaceuticals (ARZ) Shares Down 8.2%” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://sportsperspectives.com/2018/02/09/aralez-pharmaceuticals-arz-shares-down-8-2.html.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply